WO2005101014A3 - Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases - Google Patents

Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases Download PDF

Info

Publication number
WO2005101014A3
WO2005101014A3 PCT/EP2005/051677 EP2005051677W WO2005101014A3 WO 2005101014 A3 WO2005101014 A3 WO 2005101014A3 EP 2005051677 W EP2005051677 W EP 2005051677W WO 2005101014 A3 WO2005101014 A3 WO 2005101014A3
Authority
WO
WIPO (PCT)
Prior art keywords
kcnc1
disease
alzheimer
gene
provides
Prior art date
Application number
PCT/EP2005/051677
Other languages
French (fr)
Other versions
WO2005101014A2 (en
Inventor
Johannes Pohlner
Der Kammer Heinz Von
Jozef Hanes
Original Assignee
Evotec Neurosciences Gmbh
Johannes Pohlner
Der Kammer Heinz Von
Jozef Hanes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh, Johannes Pohlner, Der Kammer Heinz Von, Jozef Hanes filed Critical Evotec Neurosciences Gmbh
Priority to EP05733475A priority Critical patent/EP1735626A2/en
Priority to US11/578,419 priority patent/US20080051334A1/en
Priority to JP2007507806A priority patent/JP2007532610A/en
Publication of WO2005101014A2 publication Critical patent/WO2005101014A2/en
Publication of WO2005101014A3 publication Critical patent/WO2005101014A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a novel protein encoded by the KCNC1 gene and discloses the differential expression of the gene KCNC1 coding for KCNC1 proteins in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the KCNC1 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.
PCT/EP2005/051677 2004-04-16 2005-04-15 Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases WO2005101014A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05733475A EP1735626A2 (en) 2004-04-16 2005-04-15 Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases
US11/578,419 US20080051334A1 (en) 2004-04-16 2005-04-15 Diagnostic and Therapeutic Use of Kcnc1 for Neurodegenerative Diseases
JP2007507806A JP2007532610A (en) 2004-04-16 2005-04-15 Diagnostic and therapeutic uses of KCNC1 for neurodegenerative diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56260904P 2004-04-16 2004-04-16
US60/562,609 2004-04-16

Publications (2)

Publication Number Publication Date
WO2005101014A2 WO2005101014A2 (en) 2005-10-27
WO2005101014A3 true WO2005101014A3 (en) 2006-01-12

Family

ID=34964608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/051677 WO2005101014A2 (en) 2004-04-16 2005-04-15 Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases

Country Status (3)

Country Link
EP (1) EP1735626A2 (en)
JP (1) JP2007532610A (en)
WO (1) WO2005101014A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201120711D0 (en) 2011-12-01 2012-01-11 Univ Erasmus Medical Ct Method for classifying tumour cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006624A2 (en) * 2001-07-10 2003-01-23 Millennium Pharmaceutical, Inc. 47619 and 47621, human ion channels, and uses thereof
WO2003016475A2 (en) * 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
EP1348963A1 (en) * 2002-03-28 2003-10-01 Mitsubishi Pharma Corporation Schizophrenia related gene

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395477B1 (en) * 1998-10-23 2002-05-28 American Home Products Corporation Human potassium channel polynucleotide and polypeptides and uses thereof
GB2372502B (en) * 2000-12-12 2004-10-13 Imperial College Carbohydrate compounds containing cholesterol and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006624A2 (en) * 2001-07-10 2003-01-23 Millennium Pharmaceutical, Inc. 47619 and 47621, human ion channels, and uses thereof
WO2003016475A2 (en) * 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
EP1348963A1 (en) * 2002-03-28 2003-10-01 Mitsubishi Pharma Corporation Schizophrenia related gene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASHE P C ET AL: "Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, OXFORD, GB, vol. 25, no. 4, May 2001 (2001-05-01), pages 691 - 707, XP002305702, ISSN: 0278-5846 *

Also Published As

Publication number Publication date
EP1735626A2 (en) 2006-12-27
JP2007532610A (en) 2007-11-15
WO2005101014A2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2005108999A3 (en) Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
WO2006125830A3 (en) Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
WO2004070388A8 (en) Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases
WO2003040183A3 (en) Compounds for the diagnosis/prevention/treatment of alzheimer's disease
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
WO2004038411A3 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
WO2006134128A3 (en) Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2005085472A3 (en) Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
WO2005030947A3 (en) Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases
WO2003087403A3 (en) Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases
WO2005101014A3 (en) Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases
WO2005059562A3 (en) Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases
ATE464567T1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF F-BOX PROTEINS IN ALZHEIMER'S DISEASE AND RELATED NEURODEGENERATIVE DISEASES
WO2006008294A3 (en) Diagnostic and therapeutic use of slim3 for neurodegenerative diseases
WO2003100092A3 (en) Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
ATE534751T1 (en) USE OF PRKX FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE
WO2004035823A3 (en) Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases
WO2003085131A3 (en) Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases
WO2004020665A3 (en) Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases
WO2005071418A3 (en) Diagnostic and therapeutic use of the human dax- 1 gene and protein for neurodegenerative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005733475

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007507806

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005733475

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11578419

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11578419

Country of ref document: US